It’s always interesting when policy dots connect across events that at first seem unrelated.
A few weeks ago, Friends of Cancer Research (FOCR) held a webinar on its workstream addressing new horizons in external control arm (ECA) studies—that is, the broader problem of how regulators and clinicians should interpret evidence from single-arm trials. My April 13 blog provides a fuller report on that discussion.
Then came the April 21 Wall Street Journal editorial, framed as “Oncologists vs. FDA vs. RFK Jr.” The article argues that many oncologists were frustrated by FDA’s rejection of Replimune’s melanoma therapy RP1. But stripped of the politics and headlines, the dispute turns on a familiar methodological issue: FDA’s concern about the limits of a single-arm study and the difficulty of inferring treatment benefit from comparisons to external or historical controls.
That is essentially the same terrain explored in the FOCR webinar. The Wall Street Journal article, although filtered through a news and editorial lens, brings into practical focus many of the scientific and policy questions FOCR was discussing in a more technical setting. Read together, the two episodes underscore how central this issue has become. The key question is no longer whether external control arms will be used, but rather when they are persuasive enough, and under what conditions, to support major regulatory decisions.
